Pacanalotamab
Based on 1 Customer Validation
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines.
For research use only. We do not sell to patients.
- Purity: 97.04%
- CAS No.: 2251756-52-0
- Molecular Weight:53.69 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
(scFv-heavy-kappa)-(scFv-heavy-lambda)
Human
CD3E & TNFRSF17
Pacanalotamab (1 pg/mL-100 ng/mL; 24 h) induces BCMA-dependent tumor cell lysis via T cells activation. And Pacanalotamab induces dose-dependent redirected lysis of human multiple myeloma cell lines with EC90 values ranging from 16-810 pg/mL[1].
Pacanalotamab (100 ng/mL; 24 h) induces translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane, leading to apoptosis in MM.1R cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pacanalotamab (5 μg/kg/day; i.v. or s.c.) significant prolongs survival of mouse in mouse orthotopic L-363 xenograft model[1].
Pacanalotamab (135 μg/kg/day for i.v. or 405 μg/kg/day for s.c.; up to 28 days) is well tolerated, and it decreases plasma cells in the bone marrow in macaque in toxicity studies[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey studies[1]
-
Dosage:(1) 0, 5, 15, 45 or 135 μg/kg/day, 20 mL/kg/day; (2) 135 or 405 μg/kg/day, 2 mL/kg/day
-
Administration:Intravenous injection for (1) and subcutaneous injection for (2); for 7 days
-
Result:Showed well tolerated among Cynomolgus monkeys. Clinical signs of toxicity were limited to vomiting and increased body temperature at 4-8 h.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
(scFv-heavy-kappa)-(scFv-heavy-lambda)
ELISA, FACS, Functional assay
-
Immobilized Pacanalotamab can bind Human BCMA Protein (ECD, hFc Tag). The EC50 for this effect is 0.597 ng/mL. -
Immobilized Pacanalotamab can bind Human CD3 epsilon/CD3e Protein (ECD, hFc Tag). The EC50 for this effect is 1.506 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Pacanalotamab (HY-P99798). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2251756-52-0
-
Appearance Liquid
-
Molecular Weight 53.69 kDa
-
Color Colorless to light yellow
-
SMILES
[Pacanalotamab]
-
Synonyms
AMG 420; BI-836909
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)